Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
A new study conducted by Baylor College of Medicine and presented at the American College of Cardiology Annual Scientific Session as well as the World Congress of Cardiology shows that an oral PCSK9 inhibitor called MK-0616...
Read Full NewsExplore anticipated FDA decisions on groundbreaking neurology drugs in 2026, shaping treatment options for various neurologic conditions.
As part of NeurologyLive®'s Year in Review, take a look at some of the top ongoing clinical trials in Alzheimer disease and dementia that may impact care.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 2, 2026.
Psychiatry in 2025: Year in Review
Gastroenterology in 2025: Year in Review
Weight-Adjusted Waist Index Predicts Cardiovascular Risk in Patients with T2D
1.
For relapsed or resistant DLBCL, odronextamab produced positive results.
2.
It Is Cancer in Kate Middleton.
3.
Hospitalized Kate Middleton; Sen. Paul Demands That Fauci Go To Prison; COVID Returns to Class.
4.
I Understand Why Defense Secretary Austin Kept His Prostate Cancer Quiet.
5.
U.S. Nurse Found Dead; Harvey Weinstein's Cancer; Creepy Source of Ear Pain
1.
AI-Driven Chemotherapy: Transforming Cancer Care with Precision and Efficiency
2.
Lymphomatoid Papulosis: What You Need to Know
3.
KEYNOTE-826: Optimizing Outcomes in Persistent, Recurrent, or Metastatic Cervical Cancer
4.
Cemiplimab: A Revolutionary Drug For Treating Cancer
5.
Colon Cancer Staging: What You Need to Know
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part VI
2.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part I
3.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part V
4.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
5.
CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge